Dasatinib‐therapy induced sustained remission in a child with refractory TCF7‐SPI1 T‐cell acute lymphoblastic leukemia

The prognosis of patients with T‐cell acute lymphoblastic leukemia (T‐ALL) has been largely lacked behind than that of patients with B‐cell ALL, especially in refractory or relapsed cases. Here, we describe a 4.7‐year‐old male child with TCF‐SPI1‐postitve T‐ALL who developed refractoriness disease after a seven drugs‐conventional therapy. Several studies have suggested the therapeutic potential of dasatinib in refractory T‐ALL. Actually, dasatinib‐included therapy dramatically reduces the leukemic burden and re‐induces this patient into complete remission without systemic adverse events. Although this is a single exceptional case, the translational potential evidence of dasatinib in specific T‐ALL subtype should not be under‐estimated.

[1]  Ira W. Deveson,et al.  Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia , 2021, Nature Communications.

[2]  Cheng Cheng,et al.  Prognostic Factors for CNS Control in Children with Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation. , 2021, Blood.

[3]  M. Relling,et al.  Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia , 2021, Nature Cancer.

[4]  O. Heidenreich,et al.  Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia , 2020, Haematologica.

[5]  Cheng Cheng,et al.  Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. , 2020, JAMA oncology.

[6]  C. Mosse,et al.  Sustained remission in a patient with PDGFR‐beta‐rearranged T‐lymphoblastic lymphoma and complete remission with dasatinib , 2020, Pediatric blood & cancer.

[7]  M. Loh,et al.  Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Ossenkoppele,et al.  In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL , 2017, Blood Cancer Journal.

[9]  S. Miyano,et al.  Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia , 2017, Nature Genetics.

[10]  J. Downing,et al.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Eisenstat,et al.  Feasibility of dasatinib in children and adolescents with new or recurrent central nervous system germinoma , 2013, Pediatric blood & cancer.

[12]  A. Zieske,et al.  Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t‐cell acute lymphoblastic leukemia and ABL1 amplification , 2012, Pediatric blood & cancer.

[13]  H. Beverloo,et al.  Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia , 2009, Leukemia.

[14]  S. Mustjoki,et al.  Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. , 2008, Blood.